Compare Logitech International SA (LOGI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Medpace Holdings Inc — how do they compare? Logitech International SA trades at $98.27 (market cap $14.46B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Logitech International SA pays a 1.63% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Medpace Holdings Inc for 14 Days on average.
| LOGI | MEDP | |
|---|---|---|
Market Cap | $14.46B | $16.82B |
Volume | 349,547 | 223,093 |
Sector | Technology | Health |
52-Week High | $126.69 | $630.19 |
52-Week Low | $85.84 | $393.42 |
Typical Hold Time | 92 Days | 14 Days |
Enterprise Value | $12.79B | $16.44B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.50, down 0.67% on the day, with a neutral technical signal and key support at $100. The company demonstrates strong fundamentals with a 16.28% net income margin and consistent earnings beats in recent quarters. Recent product launches like the Zone Vibe Pro headset and partnership with SEGA for Crazy Taxi: World Tour highlight ongoing innovation. Cash flow trends show robust operational performance, with 2025 operating cash flow of $842.56 million.
The outlook is cautiously optimistic, supported by a consensus price target of $107.00 implying modest upside. Investment opportunities include sustained profitability and strategic growth initiatives, while risks involve competitive pressures and potential supply chain disruptions as noted in recent CEO commentary. Analyst sentiment is mixed with a Hold-heavy consensus, reflecting balanced near-term expectations.
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
